UK Zocor Experience Inadequate To Sway FDA Panel On Mevacor
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck could have benefited from a minimum of one-year UK consumer-use data of 10 mg simvastatin before facing a panel with its lovastatin 20 mg switch proposal in the U.S